WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that investors, journalists and the general public are invited to listen to a live webcast of the Company’s analyst and investor community meeting on September 18, 2015.
The event will focus on ImmunoGen’s strong foundation for growth, including the advancement of its multi-product pipeline, its proprietary technology that is enabling the development of novel anticancer therapies and the Company’s core competencies that position it for success.
The video webcast will begin at 8:30 a.m. ET and will be accessible through the Investors section of the Company’s website, www.immunogen.com. The meeting is expected to last approximately three hours, including a short break. An archive of the webcast will be available on the Company’s website through October 2, 2015.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The Company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche’s Kadcyla® is the first marketed product with ImmunoGen’s ADC technology. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.